Citations

Clear

127 citation(s) found for "McCormick, A".

Lack of gene complementation prevents expression of I-Ek in recombinant A.TFR5.
McCormick, John F., David, Chella S., Lafuse, William P.

Mayo Clinic

The Journal of Immunology | December 30, 2022 | Volume: 124 | Issue: 5 | Pages: 2511-2513

10.4049/jimmunol.124.5.2511 Get It

Abstract The I-E molecule is produced by complementation of genes in I-A (Ae) and I-E (E alpha). Ia specificities 22 and 23 are generated by the hybrid molecule, whereas Ia.7 is an allotypic determinant presumably on the alpha-chain of the I-E molecule. Recombinant A.TFR5 (AfEk) lacks detectable I-E molecule since Af and Ek cannot complement. In a cross between A.TFR5 and B10.A(4R) (AkEb), Aek and E alpha k can successfully complement to express the I-Ek molecule on the cell surface of the heterozygote. Haplotypes H-2b and H-2s can also provide the permissive Abe and Ase molecules for complementation with Ek alpha of A.TFR5.
Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder
Wingerchuk, Dean M. , McCormick, Dana, Barron, Sasha, Simone, Laura, Jarzylo, Larissa A., Weinshenker, Brian G.

Mayo Clinic

Journal of Managed Care & Specialty Pharmacy | November 25, 2022 | Volume: 28 | Issue: 12-a Suppl | Pages: S3-S27

10.18553/jmcp.2022.28.12-a.s1 | PMID 36427336 Get It

Silmitasertib plus gemcitabine and cisplatin first‐line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study
Borad, Mitesh J. , Bai, Li‐Yuan , Richards, Donald, Mody, Kabir , Rha, Sun Young , Tse, Emmett, O’Brien, Daniel R. , Bayat, Ahmad, Ahn, Daniel H. , Davis, S. Lindsey, Oh, Do‐Youn , Borad, Mitesh J , Hubbard, Joleen M. , Soong, John, McCormick, Daniel, Bayat, Ahmad, Park, Joon Oh

Mayo Clinic

Hepatology | September 24, 2022 | Volume: 77 | Issue: 3 | Pages: 760-773

10.1002/hep.32804 | PMID 36152015 Get It

Background and Aims: This study aimed to investigate safety and efficacy of silmitasertib, an oral small molecule casein kinase 2 inhibitor, plus gemcitabine and cisplatin (G+C) versus G+C in locally advanced/metastatic cholangiocarcinoma. Approach and Results: This work is a Phase 1b/2 study (S4‐13‐001). In Phase 2, patients received silmitasertib 1000 mg twice daily for 10 days with G+C on Days 1 and 8 of a 21‐day cycle. Primary efficacy endpoint was progression‐free survival (PFS) in the modified intent‐to‐treat population (defined as patients who completed at least one cycle of silmitasertib without dose interruption/reduction) from both phases (silmitasertib/G+C n = 55, G+C n = 29). The response was assessed by Response Evaluation Criteria in Solid Tumors v1.1. The median PFS was 11.2 months (95% confidence interval [CI], 7.6, 14.7) versus 5.8 months (95% CI, 3.1, not evaluable [NE]) ( p = 0.0496); 10‐month PFS was 56.1% (95% CI, 38.8%, 70.2%) versus 22.2% (95% CI, 1.8%, 56.7%); and median overall survival was 17.4 months (95% CI, 13.4, 25.7) versus 14.9 months (95% CI, 9.9, NE) with silmitasertib/G+C versus G+C. Overall response rate was 34.0% versus 30.8%; the disease control rate was 86.0% versus 88.5% with silmitasertib/G+C versus G+C. Almost all silmitasertib/G+C (99%) and G+C (93%) patients reported at least one treatment emergent adverse event (TEAE). The most common TEAEs (all grades) with silmitasertib/G+C versus G+C were diarrhea (70% versus 13%), nausea (59% vs. 30%), fatigue (47% vs. 47%), vomiting (39% vs. 7%), and anemia (39% vs. 30%). Twelve patients (10%) discontinued treatment because of TEAEs during the study. Conclusions: Silmitasertib/G+C demonstrated promising preliminary evidence of efficacy for the first‐line treatment of patients with locally advanced/metastatic cholangiocarcinoma.
Meniscal Extrusion
Kaiser, Joshua T. , Damodar, Dhanur , Udine, Matthew , Meeker, Zachary D. , McCormick, Johnathon R. , Wagner, Kyle R. , Krych, Aaron J. , Chahla, Jorge , Cole, Brian J. , Udine, Matthew J , Chahla, Jorge A , Krych, Aaron J

Mayo Clinic

JBJS Reviews | August 5, 2022 | Volume: 10 | Issue: 7 | Pages: No page available

10.2106/jbjs.rvw.22.00019 | PMID 35922395 Get It

➢ Pathologic meniscal extrusion can compromise meniscal function, leading to increased contact forces in the tibiofemoral compartment and the acceleration of osteoarthritic changes. ➢ Extrusion is typically defined as radial displacement of ≥3 mm outside the tibial border and is best diagnosed via magnetic resonance imaging, although ultrasonography has also demonstrated encouraging diagnostic utility. ➢ Surgical management of meniscal extrusion is based on the underlying etiology, the patient’s symptom profile, the preexisting health of the articular surface, and the risk of future chondral injury and osteoarthritis.
Extramedullary Acute Myeloid Leukemia in the De Novo Setting: Clinicopathologic Characteristics, Molecular Analysis, and Treatment Outcomes
Kuhlman, Justin J. , McCormick, Benjamin J. , Jiang, Liuyan , Menke, David M. , Badar, Talha , Kharfan‐Dabaja, Mohamed A. , Foran, James M. , Rahman, Zaid Abdel , Rahman, Zaid H. Abdel , Abdel Rahman, Zaid H , Badar, Talha , Kuhlman, Justin , Murthy, Hemant S.

Mayo Clinic

No container title available | July 22, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1832465/v1 Get It

Abstract Extramedullary disease in acute myeloid leukemia (AML), also known as myeloid sarcoma (MS), is an uncommon presentation of de novo AML. We analyzed medical records of patients in the Mayo Clinic database spanning between 1996 and 2021 who were diagnosed with de novo extramedullary AML. Survival outcomes were analyzed using Kaplan-Meier and Cox-proportional hazard models for univariate and multivariate analysis, respectively. With a median follow-up of 20.7 months, 83 patients with de novo MS were identified; 49 presented with synchronous MS and 34 with isolated MS. Next generation sequencing (NGS) revealed RTK-RAS pathway mutations in 44% of patients. Median overall survival (OS) was 25.3 months and 17.8 months in isolated and synchronous MS, respectively (p = 0.49). Variables associated with improved OS on univariate analysis included treatment with intensive chemotherapy (p < 0.001), normal or favorable risk karyotype (p = 0.001), age less than 60 years (p = 0.001), and a complete response to treatment at extramedullary sites (p < 0.0001). On multivariate analysis, normal or favorable risk karyotype (p = 0.001), age less than 60 (p = 0.01), and a complete extramedullary response (p = 0.001) were associated with improved OS. Localized therapy did not provide added survival benefit in isolated MS. Genomic stratification, age, and extramedullary site response are predictive of survival outcomes.
Risk of Postoperative Thromboembolism in Men Undergoing Urological Prosthetic Surgery: An Assessment of 21,413 Men
Hebert, Kevin , Matta, Rano , Horns, Joshua J. , Paudel, Niraj, Das, Rupam , Köhler, Tobias , McCormick, Benjamin J. , Hotaling, James M. , Myers, Jeremy B. , Hebert, Kevin J , McCormick, Benjamin J , Myers, Jeremy B , Pastuszak, Alexander W.

Mayo Clinic

Journal of Urology | June 10, 2022 | Volume: 208 | Issue: 4 | Pages: 878-885

10.1097/ju.0000000000002801 | PMID 35686836 Get It

Clinicopathologic characteristics and treatment outcomes of de novo myeloid sarcoma.
McCormick, Benjamin J. , Foran, James M. , Kuhlman, Justin J. , Badar, Talha , Rahman, Zaid Abdel , Murthy, Hemant S.

Mayo Clinic

Journal of Clinical Oncology | June 6, 2022 | Volume: 40 | Issue: 16_suppl | Pages: e19002-e19002

10.1200/jco.2022.40.16_suppl.e19002 Get It

e19002 Background: Extramedullary disease in acute myeloid leukemia (AML), also known as myeloid sarcoma (MS), is an uncommon presentation of de novo AML. Clinicopathologic characteristics and optimal treatment strategies of de novo MS remain unclear in both isolated MS without bone marrow (BM) involvement and synchronous MS with BM involvement. Methods: In a single-site retrospective study, medical records of patients with de novo extramedullary AML who received oncological care at any Mayo Clinic site between 1996 and 2021 were analyzed. Using BlueSky Statistics software, survival outcomes were analyzed using Kaplan-Meier and Cox-proportional hazard models for univariate and multivariate analysis, respectively. Results: 83 patients with de novo MS were identified; 49 (59%) presented with synchronous MS and 34 (41%) exhibited isolated MS. Median age at diagnosis was 56 years (range, 17-89); 63% were male. Next-generation sequencing of the blood +/- BM revealed abnormalities in 24/27 (88%) analyzed patients; aberrations included mutations in RTK-RAS pathways (12/27), NPM1 (10/27), TET2 (6/27), and IDH2 (4/27). Median length of follow-up was 1.73 years (95% CI; 0.03-3.0); 53 patients (64%) had expired. Median event free survival was 0.64 years and 0.61 years in isolated and synchronous MS, respectively (p = 0.5). Median overall survival (mOS) in isolated and synchronous MS was 2.1 years and 1.5 years, respectively (p = 0.5). Induction treatment with intensive chemotherapy (IC) was administered in 70 patients (84%). IC regimens included 7+3, MEC, CLAG-M, and hyper-CVAD. Variables associated with improved survival in both groups included treatment with IC +/- allogenic stem cell transplant (alloSCT) (p < 0.001), normal or favorable risk karyotype (p = 0.001), and age less than 60 (p = 0.001). Localized therapy (LT) did not provide an added survival benefit. Patients with synchronous MS were more likely to relapse in the BM and blood than isolated MS (p = 0.02). Conclusions: Enriched with RTK-RAS mutations, de novo MS remains an aggressive form of AML, particularly in patients with intermediate or high-risk genomics or those with skin, soft tissue, or lymphatic involvement. IC should be employed with consideration of alloSCT in eligible patients, particularly in synchronous MS due to a heightened risk for medullary and leukemic relapse.[Table: see text]
A Pilot Study of an Expanded Genicular Nerve Radiofrequency Ablation Protocol for the Treatment of Chronic Knee Pain
Tate, Quinn , Meiling, James B. , McCormick, Zachary L. , McCormick, Zachary L , Meiling, James B , Burnham, Taylor , Conger, Aaron

Mayo Clinic

Pain Medicine | November 12, 2021 | Volume: 23 | Issue: 3 | Pages: 599-602

10.1093/pm/pnab329 | PMID 34791455 Get It

Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group
Hurley, Robert W. , Adams, Meredith C B , Barad, Meredith , Bhaskar, Arun , Bhatia, Anuj , Deer, Timothy R. , Hah, Jennifer M. , Hooten, W. Michael , Lee, David Wonhee, McCormick, Zachary L. , Schneider, Byron J. , Eerd, Maarten van , Zundert, Jan Van , Wallace, Mark S. , Wilson, Sara M, Zhao, Zirong , Chadwick, Andrea , Deer, Tim , Hooten, W Michael , Moon, Jee Youn , Narouze, Samer , Cohen, Steven P , van Zundert, Jan , Hurley, Robert W , Barad, Meredith J , Hah, Jennifer M , Bhatia, Anuj , Kissoon, Narayan , Narouze, Samer , Provenzano, David , Cohen, Steven P.

Mayo Clinic

Regional Anesthesia & Pain Medicine | November 11, 2021 | Volume: 47 | Issue: 1 | Pages: 3-59

10.1136/rapm-2021-103031 | PMID 34764220 Get It

Background The past two decades have witnessed a surge in the use of cervical spine joint procedures including joint injections, nerve blocks and radiofrequency ablation to treat chronic neck pain, yet many aspects of the procedures remain controversial. Methods In August 2020, the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine approved and charged the Cervical Joint Working Group to develop neck pain guidelines. Eighteen stakeholder societies were identified, and formal request-for-participation and member nomination letters were sent to those organizations. Participating entities selected panel members and an ad hoc steering committee selected preliminary questions, which were then revised by the full committee. Each question was assigned to a module composed of 4–5 members, who worked with the Subcommittee Lead and the Committee Chairs on preliminary versions, which were sent to the full committee after revisions. We used a modified Delphi method whereby the questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was reached. Before commencing, it was agreed that a recommendation would be noted with >50% agreement among committee members, but a consensus recommendation would require ≥75% agreement. Results Twenty questions were selected, with 100% consensus achieved in committee on 17 topics. Among participating organizations, 14 of 15 that voted approved or supported the guidelines en bloc, with 14 questions being approved with no dissensions or abstentions. Specific questions addressed included the value of clinical presentation and imaging in selecting patients for procedures, whether conservative treatment should be used before injections, whether imaging is necessary for blocks, diagnostic and prognostic value of medial branch blocks and intra-articular joint injections, the effects of sedation and injectate volume on validity, whether facet blocks have therapeutic value, what the ideal cut-off value is for designating a block as positive, how many blocks should be performed before radiofrequency ablation, the orientation of electrodes, whether larger lesions translate into higher success rates, whether stimulation should be used before radiofrequency ablation, how best to mitigate complication risks, if different standards should be applied to clinical practice and trials, and the indications for repeating radiofrequency ablation. Conclusions Cervical medial branch radiofrequency ablation may provide benefit to well-selected individuals, with medial branch blocks being more predictive than intra-articular injections. More stringent selection criteria are likely to improve denervation outcomes, but at the expense of false-negatives (ie, lower overall success rate). Clinical trials should be tailored based on objectives, and selection criteria for some may be more stringent than what is ideal in clinical practice.
Consensus practice guidelines on interventions for cervical spine (facet) joint pain from a multispecialty international working group
Hurley, Robert W. , Adams, Meredith C B , Barad, Meredith , Bhaskar, Arun , Bhatia, Anuj , Deer, Timothy R. , Hah, Jennifer M. , Hooten, W. Michael , Lee, David Wonhee, McCormick, Zachary L. , Schneider, Byron J. , Eerd, Maarten van , Zundert, Jan Van , Wallace, Mark S. , Wilson, Sara M, Zhao, Zirong , Chadwick, Andrea , Deer, Tim , Hooten, W Michael , Moon, Jee Youn , Narouze, Samer , Cohen, Steven P , van Zundert, Jan , Hurley, Robert W , Barad, Meredith J , Hah, Jennifer M , Bhatia, Anuj , Kissoon, Narayan , Narouze, Samer , Provenzano, David , Cohen, Steven P.

Mayo Clinic

Pain Medicine | October 1, 2021 | Volume: 22 | Issue: 11 | Pages: 2443-2524

10.1093/pm/pnab281 | PMID 34788462 Get It

Abstract Background The past two decades have witnessed a surge in the use of cervical spine joint procedures including joint injections, nerve blocks and radiofrequency ablation to treat chronic neck pain, yet many aspects of the procedures remain controversial. Methods In August 2020, the American Society of Regional Anesthesia and Pain Medicine and the American Academy of Pain Medicine approved and charged the Cervical Joint Working Group to develop neck pain guidelines. Eighteen stakeholder societies were identified, and formal request-for-participation and member nomination letters were sent to those organizations. Participating entities selected panel members and an ad hoc steering committee selected preliminary questions, which were then revised by the full committee. Each question was assigned to a module composed of 4–5 members, who worked with the Subcommittee Lead and the Committee Chairs on preliminary versions, which were sent to the full committee after revisions. We used a modified Delphi method whereby the questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was reached. Before commencing, it was agreed that a recommendation would be noted with &gt;50% agreement among committee members, but a consensus recommendation would require ≥75% agreement. Results Twenty questions were selected, with 100% consensus achieved in committee on 17 topics. Among participating organizations, 14 of 15 that voted approved or supported the guidelines en bloc, with 14 questions being approved with no dissensions or abstentions. Specific questions addressed included the value of clinical presentation and imaging in selecting patients for procedures, whether conservative treatment should be used before injections, whether imaging is necessary for blocks, diagnostic and prognostic value of medial branch blocks and intra-articular joint injections, the effects of sedation and injectate volume on validity, whether facet blocks have therapeutic value, what the ideal cut-off value is for designating a block as positive, how many blocks should be performed before radiofrequency ablation, the orientation of electrodes, whether larger lesions translate into higher success rates, whether stimulation should be used before radiofrequency ablation, how best to mitigate complication risks, if different standards should be applied to clinical practice and trials, and the indications for repeating radiofrequency ablation. Conclusions Cervical medial branch radiofrequency ablation may provide benefit to well-selected individuals, with medial branch blocks being more predictive than intra-articular injections. More stringent selection criteria are likely to improve denervation outcomes, but at the expense of false-negatives (ie, lower overall success rate). Clinical trials should be tailored based on objectives, and selection criteria for some may be more stringent than what is ideal in clinical practice.